logo-loader
viewMatinas BioPharma

Full interview: Matinas BioPharma to begin dosing HIV patients with cryptococcal meningitis in Phase 2 studies

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) CEO Jerome Jabbour tells Proactive it will begin a Part 2 study of MAT2203 for the treatment of HIV patients with cryptococcal meningitis.

Jabbour explains how the New Jersey-based company will begin dosing its first patient in the upcoming weeks and expects to provide updates on the anticipated progression from patient cohort to cohort throughout 2020.

Quick facts: Matinas BioPharma

Price: 0.5369 USD

NYSE:MTNB
Market: NYSE
Market Cap: $105.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Matinas BioPharma named herein, including the promotion by the Company of Matinas BioPharma in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Matinas BioPharma raises $50M to fund drug development,...

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) CEO Jerome Jabbour tells Proactive the New Jersey-based company has closed a registered public offering of its stock, raising around $50 million gross. What's more, Jabbour commented on its peers' recent data in the Omega 3 area, how this...

on 01/21/2020

2 min read